TXG

10x GenomicsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$27.18

-11.5% vs current

Most likely

Base case

60%

Probability

Target price

$18.54

-39.6% vs current

B-

Bear case

20%

Probability

Target price

$12.68

-58.7% vs current

AI sentiment snapshot

Latest data as of 2026-02-14

AI commentary

Market sentiment is cautiously neutral: analyst medians cluster near the current price, implying limited consensus upside. Coverage shows wide dispersion (median ~$18.54, high outlier $57), reflecting polarized views on growth and adoption. Investors are focused on execution—consumables attach rates and margin inflection are the key swing factors.

RankAlpha Sentiment AI - 2026-02-14

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystNext quarterly earnings (estimated)High impact

Company quarterly results can drive near-term volatility; expectations and consensus targets are mixed in public sources [#SERP-3]. Using a conservative estimate for the next report window.[#SERP-3]

2026-12-31eventProduct launches / regulatory milestones (pipeline)High impact

Discrete product launches or regulatory/clearance milestones would be event-driven price movers; timing is uncertain so we assume a year-end window for planning.[#SERP-1]

2027-02-14catalystCommercial adoption of expanded multi-omics productsHigh impact

Broader market adoption of new product lines and multi-omics expansion could materially increase revenue over a multi-year horizon; consensus analyst notes emphasize platform opportunity [#SERP-4].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-02-14 • Updated nightlySource: Internal modelMethodology